Given that inhibition of STAT3 activity has been linked with sensitizing resistant cells to chemotherapy [51], we examined the effects of paclitaxel, a chemotherapeutic drug commonly used to treat breast cancer, as well as bleomycin and capsazepine, two ROS-inducing agents, on the proliferation of MDA-MB-231 cells. The gene discussed is STAT3; the disease is breast cancer.